BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 22, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analysts Picks & Changes

Analysts Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 6/19 cls
Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) Piper Jaffray Edward Tenthoff Price target Buy 46% $2.52
Tenthoff lowered his target to $4 from $5 to account for the dilution of shares following Alexza's acquisition of Symphony Allegro Inc. Under the terms of the acquisition, Symphony Allegro founding investor Symphony Capital will receive 10M shares (see "Meno Mosso," A16).
BioDelivery Sciences International Inc. (NASDAQ:BDSI) Ladenburg Thalmann Matthew Kaplan Price target Buy -2% $6.64
Kaplan raised his target to $9 from $6.50 after BioDelivery said it had reached agreement with FDA on all aspects of the NDA for Onsolis (formerly BEMA) fentanyl, including the Risk Evaluation and Mitigation Strategy (REMS). Kaplan expects approval by July for the adhesive disc formulation of fentanyl to...

Read the full 765 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >